RECCE PHARMACEUTICALS LTD — Director's Dealing 2020

Jul 12, 2020

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Recce Pharmaceuticals Ltd (Company) ABN 73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

the director for the purposes of section	205G of the Corporations Act.
Name of Director	James Hamilton Bray Graham
Date of last notice	19 December 2019

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving riseto the relevant interest.	N/A
Date of change	9 July 2020
No. of securities held prior tochange	Direct Interest:1. 2,060,908 ordinary shares2. 389,712 Class B Performance Shares3. 389,712 Class C Performance Shares4. 389,712 Class D Performance SharesIndirect Interest:Mr. James Graham <J Graham Family A/c>1. 1,781,250 ordinary shares2. 356,250 Class B Performance Shares3. 356,250 Class C Performance Shares4. 356,250 Class D Performance SharesBulleen Pty Ltd1. 650,000 ordinary shares

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Class	Fully Paid Ordinary Shares and Class CPerformance Shares	Fully Paid Ordinary Shares and Class CPerformance Shares
Number acquired	745,962 fully paid ordinary shares (uponconversion of 745,962 Class C PerformanceShares)
Number disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details andestimated valuation	Nil
No. of securities held after change	Direct Interest:1. 2,450,620 ordinary shares2. 389,712 Class B Performance Shares3. 389,712 Class D Performance SharesIndirect Interest:Mr. James Graham <J Graham Family A/c>1. 2,137,500 ordinary shares2. 356,250 Class B Performance Shares3. 356,250 Class D Performance SharesBulleen Pty Ltd1. 650,000 ordinary shares
Nature of changeExample: on-market trade, off-market trade, exerciseof options, issue of securities under dividendreinvestment plan, participation in buy-back	Conversion of 745,962 Class C PerformanceShares
Part 2 – Change of director’s interests in contractsNote: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” shouldbe disclosed in this part.
Detail of contract		N/A
Nature of interest		N/A
Name of registered holder(if issued securities)		N/A
Date of change		N/A
No. and class of securities to which interest related prior tochangeNote: Details are only required for a contract in relation to which the interest has changed		N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Part 3 – +Closed period
Were the interests in the securities or contracts detailed abovetraded during a+closed period where prior written clearance wasrequired?	No
If so, was prior written clearance provided to allow the trade toproceed during this period?	N/A
If prior written clearance was provided, on what date was thisprovided?	N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3